{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:53:47Z","timestamp":1786737227765,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharm Bioall Sci"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jpbs.jpbs_154_20","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T07:15:33Z","timestamp":1597994133000},"page":"538","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and adverse events of delafloxacin for treating acute bacterial skin and skin structure infections: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"12","author":[{"given":"SyedSaad Bin","family":"Qasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SyedBilal","family":"Tanvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Latimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FayezHussain","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0975-7406.292838-1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key-10.4103\/0975-7406.292838-2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3947\/ic.2017.49.4.301","article-title":"Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection","author":"Kwak","year":"2017","journal-title":"Infect Chemother"},{"key":"key-10.4103\/0975-7406.292838-3","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"key-10.4103\/0975-7406.292838-4","doi-asserted-by":"crossref","unstructured":"Markham A Ibalizumab: first global approval. Drugs 2018;78:781-5.","DOI":"10.1007\/s40265-018-0907-5"},{"key":"key-10.4103\/0975-7406.292838-5","doi-asserted-by":"crossref","unstructured":"Fernandes P, Martens E Antibiotics in late clinical development. Biochem Pharmacol 2017;133:152-63.","DOI":"10.1016\/j.bcp.2016.09.025"},{"key":"key-10.4103\/0975-7406.292838-6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ofid\/ofv133.493","article-title":"Results of a global phase 3 study of delafloxacin (DLX) compared to vancomycin with aztreonam (VAN) in acute bacterial skin and skin structure infections (ABSSSI)","author":"Cammarata","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"key-10.4103\/0975-7406.292838-7","doi-asserted-by":"crossref","unstructured":"Kemeny L, Lucasti C, Sun E, Quintas M, Lawrence L, Cammarata S Outcomes in obese patients with acute bacterials skin and skin structure infections (ABSSSI) in a trial comparing delafloxacin to vancomycin\/aztreonam. Open Forum Infect Dis 2015;2:S49.","DOI":"10.1093\/ofid\/ofv133.500"},{"key":"key-10.4103\/0975-7406.292838-8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/jac\/dkv411","article-title":"A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin","author":"Kingsley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0975-7406.292838-9","doi-asserted-by":"crossref","unstructured":"O\u2019Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 2015;30:67-73.","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"key-10.4103\/0975-7406.292838-10","doi-asserted-by":"crossref","unstructured":"Giordano P, Pullman J, Lawrence L, Quintas M, Tseng C, Cammarata SK Impact of delafloxacin (DLX) and vancomycin\/aztreonam (VAN\/AZ) on resolution of signs and symptoms of acute bacterial skin and skin structure infections (ABSSSI). Open Forum Infect Dis 2017;4:S531-2.","DOI":"10.1093\/ofid\/ofx163.1384"},{"key":"key-10.4103\/0975-7406.292838-11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2015.11.019","article-title":"Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers","author":"Hoover","year":"2016","journal-title":"Clin Ther"},{"key":"key-10.4103\/0975-7406.292838-12","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2147\/IDR.S202160","article-title":"Efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections: a systematic review and meta-analysis of randomized controlled trials","author":"Lan","year":"2019","journal-title":"Infect Drug Resist"},{"key":"key-10.4103\/0975-7406.292838-13","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0975-7406.292838-14","doi-asserted-by":"crossref","unstructured":"Pfaller MA, Sader HS, Rhomberg PR, Flamm RK In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother2017;61:e02609-16.","DOI":"10.1128\/AAC.02609-16"},{"key":"key-10.4103\/0975-7406.292838-15","doi-asserted-by":"crossref","unstructured":"Righi E, Carnelutti A, Vena A, Bassetti M Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. Infect Drug Resist 2018;11:479-88.","DOI":"10.2147\/IDR.S142140"},{"key":"key-10.4103\/0975-7406.292838-16","doi-asserted-by":"crossref","unstructured":"Jorgensen SCJ, Mercuro NJ, Davis SL, Rybak MJ Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther 2018;7:197-217.","DOI":"10.1007\/s40121-018-0198-x"}],"container-title":["Journal of Pharmacy And Bioallied Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:51:47Z","timestamp":1786733507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.JPBS_154_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["292838"],"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_154_20","relation":{},"ISSN":["0975-7406"],"issn-type":[{"value":"0975-7406","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}